Fennec Pharmaceuticals
FENC
30 hedge funds and large institutions have $36M invested in Fennec Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 20 closing their positions.
3.27% less ownership
Funds ownership: 48.44% → 45.17% (-3.3%)
23% less capital invested
Capital invested by funds: $46.7M → $36M (-$10.8M)
39% less funds holding
Funds holding: 49 → 30 (-19)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
85% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$3.6M |
| 2 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
+$237K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$230K |
| 4 |
Millennium Management
New York
|
+$202K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$119K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.13M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.42M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$1.27M |
| 4 |
State Street
Boston,
Massachusetts
|
-$812K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$223K |
FENC Hedge Fund Activity: Q2 2019 in Review
30 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2019, worth a combined $36M — down 23% from $46.7M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of FENC and 3 opened new positions — a net loss of 17 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Solas Capital Management, opening a new position worth an estimated $3.6M. The largest seller was BlackRock, cutting an estimated $2.13M.
- 30 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2019, down from 49 in Q1 2019.
- Funds reported $36M of Fennec Pharmaceuticals stock for Q2 2019, down 23% quarter-over-quarter.
- 3 funds opened new Fennec Pharmaceuticals positions in Q2 2019 and 20 closed out, a net change of -17 holders.
- The largest Fennec Pharmaceuticals buyer in Q2 2019 was Solas Capital Management, an estimated $3.6M added.
- The largest Fennec Pharmaceuticals seller in Q2 2019 was BlackRock, an estimated $2.13M sold.
Based on aggregated 13F filings for Q2 2019.